The study focused on house dust mite allergy, one of the most common and persistent triggers of allergic rhinitis worldwide. The researchers enrolled 28 patients with house dust mite-induced allergic rhinitis who completed six months of subcutaneous immunotherapy, the classic injection-based treatment in which gradually increasing doses of allergen are administered to retrain the immune system. To ensure that the metabolic changes they observed were meaningful, they required that every enrolled patient achieved at least a 50 percent reduction in total visual analogue scale symptom score over the course of treatment. Alongside these patients, the team recruited 19 non-atopic healthy controls to serve as a reference point for the healthy state.

The sampling design was deliberately paired. Plasma and nasal secretion samples were collected from the patients both before and after the six-month immunotherapy course, while the healthy controls provided a single set of samples. In total, the study yielded 150 biospecimens. Each specimen was subjected to untargeted liquid chromatography-mass spectrometry metabolomics, an analytical approach that captures thousands of small molecules without presupposing which ones matter. After rigorous quality control, the dataset retained 831 metabolites in plasma and 989 metabolites in nasal secretions, providing an unusually rich dual-compartment view of allergic biology.

The first major finding was that the disease signal is far broader in the nose than in the blood. Applying a false discovery rate-adjusted threshold to control for the enormous number of statistical comparisons inherent in metabolomics, the team identified 500 nasal secretion metabolites and 208 plasma metabolites associated with allergic rhinitis when compared with healthy controls. In other words, the local mucosal compartment carried more than twice as many disease-associated metabolic features as the systemic circulation. This asymmetry makes intuitive sense, since the nasal mucosa is the direct site of allergen contact and inflammation, but quantifying it so clearly underscores how much information single-compartment monitoring has been missing.

When the researchers turned to the treatment itself, comparing each patient’s samples before and after six months of subcutaneous immunotherapy, they found 98 treatment-responsive metabolites in nasal secretions and 40 in plasma. Notably, neither compartment fully returned to the healthy-control profile after treatment. Recovery, in metabolic terms, was partial. Yet the shift toward the healthy state was more evident in nasal secretions than in plasma, suggesting that the inflamed mucosal barrier responds to immunotherapy with a more pronounced metabolic remodeling than the systemic circulation does over the same six-month window.

Pathway and trajectory analyses then revealed what the researchers describe as a division of labor between the two compartments. The plasma changes were enriched for nucleotide turnover, NAD-plus-related metabolism, and bioenergetic and redox pathways, a pattern consistent with systemic inflammatory and metabolic stress. Nasal secretions, by contrast, showed stronger remodeling of lipid, steroid, and redox-related metabolism, processes tied to the inflamed mucosal barrier and its recovery. When the team arranged the samples along a continuum from healthy control to allergic rhinitis to post-treatment, these patterns coalesced into two coordinated but temporally asynchronous axes: a plasma nucleotide and NAD-plus axis and a nasal lipid-steroid-redox axis. The two compartments, in effect, recover on different schedules and through different metabolic languages.

To make this compartment preference quantitative rather than merely descriptive, the researchers developed a novel metric called the Nasal-Plasma Contrast Index, or NPCI, computed for the 600 metabolites detected in both matrices. By integrating the NPCI with temporal clustering and differential analysis across the disease and treatment states, they prioritized 30 exploratory candidate features as the most informative metabolic signatures in the dataset. Among these, one nasal-enriched feature annotated as ATP stood out. It was significant in both the disease-state comparison and the treatment comparison, and it followed a coherent temporal trajectory across the healthy-allergic-recovery continuum, making it a leading candidate readout for future validation studies.

The team also examined whether any of the metabolic features correlated with the magnitude of symptom improvement each patient experienced. Some response-intensity signals did appear, but none of them remained statistically significant after correction for multiple testing. The authors are careful to frame these associations as hypothesis-generating rather than established findings, a level of caution that reflects the realities of untargeted metabolomics, where relative abundance and putative annotations can easily be overinterpreted without confirmatory assays.

Indeed, the study comes with a set of clearly stated limitations that any reader should keep in mind. It was not designed to establish a clinical response-prediction model. Every enrolled patient improved during immunotherapy, which means the cohort contained no non-responders, no untreated longitudinal controls, and no placebo group, so the metabolic signatures of treatment failure remain unexplored. Untargeted metabolomics also reports relative feature abundance rather than absolute concentrations, and for some metabolites the structural identification remains putative rather than definitive. The authors emphasize that prospective studies including both responders and non-responders, targeted quantitative assays, and independent validation cohorts will be required before any of the 30 candidate features can be considered for clinical use.

Even with those caveats, the conceptual contribution of the work is substantial. By sampling the nose and the blood in parallel, before and after treatment, and against a healthy reference group, the study demonstrates that local and systemic compartments carry complementary, non-redundant information about allergic disease and its resolution. The plasma nucleotide and NAD-plus axis and the nasal lipid-steroid-redox axis together sketch a map of how immunometabolic recovery unfolds during allergen immunotherapy, and the Nasal-Plasma Contrast Index offers a reusable tool for quantifying where any given metabolic signal lives. For a condition affecting hundreds of millions of people, the message is that recovery is not a single process but a coordinated duet between mucosa and circulation, and that listening to both voices may ultimately be the key to understanding who recovers, how quickly, and why.

Subject of Research: Paired nasal and plasma metabolomics of house dust mite allergic rhinitis during subcutaneous immunotherapy

Article Title: Paired nasal and plasma metabolomics reveal distinct recovery trajectories during allergy immunotherapy

Article References: Paired nasal and plasma metabolomics reveal distinct recovery trajectories during allergy immunotherapy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: allergic rhinitis, metabolomics, subcutaneous immunotherapy, house dust mite allergy, nasal secretions, plasma, NAD metabolism, lipid remodeling, Nasal-Plasma Contrast Index, biomarkers, mucosal immunity, iMetaMed

Tarlatamab is a bispecific T-cell engager, a class of engineered antibody molecules designed to bring immune cells and tumor cells into close contact so that the immune system can attack the cancer directly. The drug binds DLL3, a protein abundantly expressed on the surface of small cell lung cancer cells but largely absent from healthy tissues, on one side, and CD3 on T cells on the other. By bridging these two cell types, tarlatamab activates the patient’s own T cells against the tumor. The therapy has already demonstrated established clinical activity in small cell lung cancer when administered intravenously, and an approved intravenous regimen of 10 milligrams every two weeks is in clinical use. What has been missing until now is evidence that the drug can be delivered in a simpler way without sacrificing efficacy or safety.

DeLLphi-308 is the first study to evaluate subcutaneous administration of tarlatamab, and the rationale for exploring this route goes well beyond convenience. Intravenous infusions deliver the full dose into the bloodstream rapidly, producing high peak serum concentrations shortly after administration. Subcutaneous injection, by contrast, allows the drug to be absorbed gradually from the injection site, producing lower peak concentrations that appear over a delayed timeframe. For a bispecific T-cell engager, this pharmacokinetic difference matters. Rapid peaks are thought to contribute to cytokine release syndrome, a systemic inflammatory reaction that is the most characteristic toxicity of this drug class and a frequent reason for hospitalization and intensive monitoring. If subcutaneous dosing flattens the concentration curve, it could potentially reduce the incidence or severity of cytokine release syndrome while delivering the same total drug exposure.

The open-label, multicenter study enrolled patients with extensive-stage small cell lung cancer whose disease had progressed or recurred after at least one platinum-based therapy, the standard first-line backbone for this disease. In the first part of the study, investigators compared subcutaneous target doses of 10 milligrams and 15 milligrams, each administered every two weeks. Pharmacokinetic analysis showed that the 15 milligram subcutaneous dose achieved serum exposures comparable to the established intravenous regimen of 10 milligrams every two weeks. On the strength of that matching exposure, the 15 milligram dose was selected as the target dose for the second part of the study, where safety and preliminary antitumor activity were assessed in a larger group of patients.

As of the March 5, 2026 data cutoff, 40 patients had received the 15 milligram subcutaneous target dose. Treatment-related adverse events occurred in 85 percent of these patients, with 10 percent experiencing a grade 3 or higher event, a rate that investigators characterized as consistent with a manageable safety profile. The most common treatment-related toxicities were injection-site reactions, seen in half of the patients, and dysgeusia, a distortion of taste reported by 45 percent. Cytokine release syndrome occurred in 38 percent of patients, and decreased appetite in 20 percent. No grade 5, or fatal, treatment-related adverse events were recorded, an important benchmark for a therapy that mobilizes the immune system against cancer.

The pattern of cytokine release syndrome observed in the study was particularly notable. Events were predominantly grade 1, the mildest category, and no patient experienced grade 3 or higher cytokine release syndrome. Equally significant, no cytokine release event required dose interruption or discontinuation of therapy. For a drug class in which cytokine release has historically dictated step-up dosing schedules, hospitalization and careful monitoring, the ability to deliver full therapeutic doses subcutaneously with predominantly mild inflammatory events represents a meaningful advance in tolerability. The investigators attribute this favorable profile at least in part to the lower, delayed peak serum concentrations achieved with subcutaneous absorption.

Early efficacy signals were also encouraging. The preliminary objective response rate in the 15 milligram group was 30 percent, meaning roughly one in three patients with previously treated extensive-stage small cell lung cancer experienced measurable tumor shrinkage. In a disease where outcomes after platinum failure have historically been poor and where effective options remain scarce, this level of activity from a more convenient route of administration is a noteworthy finding. The investigators concluded that subcutaneous tarlatamab was well tolerated and that the observed safety profile, pharmacokinetic findings and preliminary antitumor activity, together with the potential convenience of subcutaneous administration, support further investigation of this approach.

The clinical implications extend beyond the numbers. Intravenous administration of bispecific therapies typically requires infusion suites, extended clinic visits and, in many protocols, initial hospitalization to manage the risk of cytokine release during the first doses. A subcutaneous formulation that can be injected quickly, with a safety profile dominated by low-grade events, could eventually allow treatment closer to home, reduce the logistical burden on patients who often travel long distances to specialized cancer centers, and expand access to an effective immunotherapy for populations currently underserved. For patients with extensive-stage small cell lung cancer, who frequently face limited life expectancy and heavy symptom burden, every reduction in treatment inconvenience carries real weight.

Speaking about the findings, Pedro Rocha, MD, of Hospital Universitari Vall d’Hebron in Barcelona, Spain, and primary author of the study, emphasized the pharmacokinetic achievement at the heart of the results. The findings from DeLLphi-308 suggest that a 15 milligram subcutaneous tarlatamab dose can achieve serum exposures comparable to the approved 10 milligram intravenous dosing administered every two weeks while maintaining a favorable safety profile, he noted. The predominantly low-grade cytokine release events and the preliminary antitumor activity, he added, support continued investigation of this more convenient route of administration. Updated data from the latest data cutoff were scheduled to be shared in an oral presentation at the conference on September 15, offering a fuller picture of both durability of response and long-term tolerability.

The DeLLphi-308 results arrive at a moment of rapid evolution in the treatment of small cell lung cancer, a disease long defined by its aggressiveness and its tendency to relapse after initial response to chemotherapy. Bispecific T-cell engagers targeting DLL3 have emerged as one of the most promising strategies for the previously treated setting, and the present study addresses the practical question of how such therapies can best be delivered. While the findings remain preliminary, based on 40 patients at a single data cutoff, the combination of matched drug exposure, predominantly mild cytokine release syndrome, no fatal treatment-related events and a 30 percent response rate provides a solid foundation for the next phase of development. If larger studies confirm these results, subcutaneous tarlatamab could become a template for how potent immune-engaging cancer therapies are administered, pairing the biological power of bispecific antibodies with the simplicity of an injection rather than an infusion.

Subject of Research: Subcutaneous administration of the bispecific T-cell engager tarlatamab in previously treated extensive-stage small cell lung cancer

Article Title: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

Article References: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-308, bispecific T-cell engager, subcutaneous immunotherapy, cytokine release syndrome, DLL3, IASLC, WCLC 2026, pharmacokinetics, extensive-stage SCLC, cancer immunotherapy